Overview
Uremic neuropathy is a neurological complication associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), characterized by sensory, motor, or autonomic nerve dysfunction due to the accumulation of uremic toxins 1.Diagnosis
Clinical Symptoms: Primarily sensory disturbances, including numbness, tingling, and pain 1.
Diagnostic Tests: Tissue biopsy and imaging studies (e.g., three-phase bone scan) may help in diagnosing related complications like calcific uremic arteriolopathy 1.
Grading: Specific grading systems for uremic neuropathy are not detailed in the provided abstracts 1.Management
First-Line Treatments: Discontinuation of calcitriol, use of non-calcium-based phosphate binders, and adjustment of dialysate calcium concentration 1.
Adjunctive Treatments: Sodium thiosulfate (STS) has been anecdotally used, administered intravenously at 25 g/1.73 m2 per dose, especially in severe cases requiring additional support like continuous venovenous hemofiltration 1.Special Populations
Pediatrics: Limited data; STS treatment explored in pediatric patients with ESRD and calcific uremic arteriolopathy, though primarily focused on management rather than neuropathy specifically 1.Key Recommendations
Discontinue calcitriol and use non-calcium-based phosphate binders to manage uremic toxin levels (Evidence: Expert opinion) 1.
Adjust dialysate calcium concentration to mitigate hypercalcemia and related complications (Evidence: Expert opinion) 1.
Consider sodium thiosulfate as an adjunctive therapy in severe cases, particularly when calcific complications are present, though evidence is primarily from case reports (Evidence: Weak) 1.References
1 Araya CE, Fennell RS, Neiberger RE, Dharnidharka VR. Sodium thiosulfate treatment for calcific uremic arteriolopathy in children and young adults. Clinical journal of the American Society of Nephrology : CJASN 2006. link